- Home
- CRBP vs PAI Comparison
CRBP vs PAI Comparison
Compare CRBP & PAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- PAI
- Stock Information
- Founded
- CRBP 2009
- PAI 1973
- Country
- CRBP United States
- PAI United States
- Employees
- CRBP N/A
- PAI N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- PAI Trusts Except Educational Religious and Charitable
- Sector
- CRBP Health Care
- PAI Finance
- Exchange
- CRBP Nasdaq
- PAI Nasdaq
- Market Cap
- CRBP 114.8M
- PAI 123.5M
- IPO Year
- CRBP N/A
- PAI N/A
- Fundamental
- Price
- CRBP $16.22
- PAI $12.71
- Analyst Decision
- CRBP Strong Buy
- PAI
- Analyst Count
- CRBP 8
- PAI 0
- Target Price
- CRBP $50.57
- PAI N/A
- AVG Volume (30 Days)
- CRBP 221.8K
- PAI 25.0K
- Earning Date
- CRBP 11-06-2025
- PAI 01-01-0001
- Dividend Yield
- CRBP N/A
- PAI 4.78%
- EPS Growth
- CRBP N/A
- PAI N/A
- EPS
- CRBP N/A
- PAI N/A
- Revenue
- CRBP N/A
- PAI N/A
- Revenue This Year
- CRBP N/A
- PAI N/A
- Revenue Next Year
- CRBP $220.00
- PAI N/A
- P/E Ratio
- CRBP N/A
- PAI N/A
- Revenue Growth
- CRBP N/A
- PAI N/A
- 52 Week Low
- CRBP $4.64
- PAI $10.59
- 52 Week High
- CRBP $20.77
- PAI $12.63
- Technical
- Relative Strength Index (RSI)
- CRBP 76.29
- PAI 46.96
- Support Level
- CRBP $15.00
- PAI $12.69
- Resistance Level
- CRBP $16.97
- PAI $12.94
- Average True Range (ATR)
- CRBP 1.01
- PAI 0.13
- MACD
- CRBP 0.28
- PAI -0.01
- Stochastic Oscillator
- CRBP 88.62
- PAI 45.73
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About PAI Western Asset Investment Grade Income Fund Inc.
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.